中文摘要：

目的：观察放化疗联合胸腔镜手术治疗ⅢAN2期非小细胞肺癌（NSCLC）患者的临床效果。方法：ⅢA期N2NSCLC患者80例．40例行胸腔镜手术为研究组。40例行传统开胸手术为对照组。术后均予诺维本联合顺铂化疗4个周期，每3周为1个周期。化疗后7～14d给予6MV—X线适形放疗50Gy／25次／35d。比较2组的1、2年生存率、完成总疗程时间及毒副反应。结果：研究组患者总疗程时间明显缩短（χ2=9．45，P=0．002），术后化疗开始时间明显缩短（χ2=41．32，P=0．00），治疗后KPS评分明显升高（χ2=15．12，P=0．002）。2组患者的骨髓抑制、消化道反应及1、2年生存率无明显差异。结论：ⅢA期N2NSCLC患者胸腔镜术后化放疗可以达到较好疗效，且手术创伤小，住院时间短，术后恢复快，可以缩短术后辅助化疗开始的时间及总的疗程时间，值得进一步研究及推广。

英文摘要：

Objective To evaluate the clinical efficacy of thoracoscopic surgery combined with chemorad-iotherapy in patients with N2 stage IliA non-small cell lung cancer （NSCLC）. Methods 40 patients （study group） received thoracoscopic surgery and another 40 patients （control group） received traditional thoracotomy. Combination therapy with navelbine and cisplatin were postoperatively administered for four cycles and one cycle lasted for 3 weeks. 7 to 14 days after chemotherapy, sequential conformal radiotherapy were delivered. The one-year survival and two-year survival rates, duration of tatal treatment, and adverse reactions were compared between the two groups. Results In the study group, duration of total treatment time and time to postoperative chemotherapy were significantly shorter （χ2 = 9.45 ,P = 0.002 and χ2 = 41.324, P = 0.000）, and the KPS score was significantly higher （χ2 = 15.118,P = 0.002）. No significant differences were found between the two groups in bone marrow suppression,gastrointestinal reactions,and one- or two-year survival rate. Conclusions As compared with conventional surgery,post-thoracoseopic surgery sequential chemoradiotherapy for patients with N2 stage II1 A NSCLC could achieve a better efficacy with less surgical trauma, shorter hospital stay, faster recovery, and shorter time to postoperative chemotherapy and total treatment duration ; it is worth further researching and popularizing.